The immune response is a central player in the recovery from, and exacerbation of, infectious disease. Human-centric, in vitro assays and physiological models that capture relevant immune responses, immunomodulatory biology, and inflamed tissue responses are critical to advance high potential treatments not only for the sequelae of viral infection but also for the assessment of candidates in any therapeutic area where an immune response may arise.
For example, in addition to Acute Respiratory Distress Syndrome (ARDS), long-term immune system, cardiovascular, and neurological effects may be consequences of SARS-CoV2 infection. And despite the availability of vaccines, long-term disease effects with immune system consequences may be a reality for patients, and clinical trial challenges may persist for biopharma. There is a critical need to develop treatments for the immune consequences of viral infection using newly discovered candidates and repurposed drugs, as individual or combination therapies, before moving to clinical trials.
Validated against clinical compounds, our Translational Biology Center of Excellence Immune Response Models provide reproducible data, actionable insights, and a smooth transition into our broader portfolio of services. Appropriate for small molecules or biologics, these models serve a variety of strategies from discovery to repurposing, and from individual to combination therapies. With these assays and their comprehensive set of clinically relevant biomarker readouts, you can gain a comprehensive assessment of a developmental or repositioned therapeutic candidate before heading into clinical trials.
- Cytokine Storm Assay
Satisfy recommendations from regulatory agencies to assess the risk of large molecules to induce acute or prolonged immunogenicity - AdapTive Immune Response Models
Select from one, two, or three systems to report on adaptive immune responses in lymph, systemic, or tissue environments - BioMAP® T Cell Autoimmune Panel
Identify translational biomarkers and benchmark to seven standards-of-care reference drugs in a platform amenable to compound screening
